Summary
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
History
IDEAYA was founded in 2017 and is headquartered in South San Francisco, California. In December, 2019 they closed venture capital financing of $100 million. IDEAYA has established collaborations with leading research institutions and biopharmaceutical companies, including Merck, GSK/Tesaro, and MD Anderson Cancer Center at the University of Texas.
Mission
IDEAYA Biosciences' mission is to develop new targeted oncology therapies by leveraging a deep understanding of the genetic drivers of cancer and combining breakthrough science with cutting-edge technologies.
Vision
IDEAYA's vision is to create a future in which cancer patients have more meaningful options and can benefit from transformative, personalized therapies.
Key Team
Dr. Jeffrey Hager Ph.D. (Co -Founder)
Mr. Andres Ruiz Briseno CPA (VP and Head of Bus. Operations & IR)
Mr. Jason S. Throne J.D., Esq. (Sr. VP, Gen. Counsel & Company Sec.)
Dr. Paul A. Barsanti Ph.D. (Sr. VP & Head of Drug Discovery)
Dr. Matthew Maurer M.D. (VP and Head of Medical Affairs & Clinical Oncology)
Mr. Mick O'Quigley (Sr. VP of Devel. Operations)
Dr. Darrin M. Beaupre M.D., Ph.D. (Sr. VP & Chief Medical Officer)
Recognition and Awards
IDEAYA has been recognized with the Rising Star Award from the 2019 National Cancer Institute's prestigious Science + Technology in Oncology Conference, as well as the 2019 SCRIP Award for Best Biotech Company, presented by the Cipher Conference.
References
United States 